Study of Durvalumab + Tremelimumab, Durvalumab, and Placebo in Limited Stage Small-Cell Lung Cancer in Patients Who Have Not Progressed Following Concurrent Chemoradiation Therapy (NCT03703297)
A Phase III, Randomized, Double-blind, Placebo-controlled, Multi-center, International Study of Durvalumab or Durvalumab and Tremelimumab as Consolidation Treatment for Patients With Limited Stage Small Cell Lung Cancer Who Have Not Progressed Following Concurrent Chemoradiation Therapy (ADRIATIC)
🩺 Plain-English Summary (8th-Grade Level)
This is a Phase III, Randomized, Double-blind, Placebo-controlled, Multi-center, International Study of Durvalumab or Durvalumab and Tremelimumab as Consolidation Treatment for Patients with LS-SCLC Who Have Not Progressed Following Concurrent Chemoradiation Therapy
Who can join: Review the eligibility criteria below.
Location: Research Site — Tucson, Arizona
Age range: 18 Years to 130 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (183 Sites)
Showing the first 25 of 183 sites.
- Research Site — Tucson, Arizona
- Research Site — Santa Rosa, California
- Research Site — New Haven, Connecticut
- Research Site — Fort Myers, Florida
- Research Site — Orange City, Florida
- Research Site — St. Petersburg, Florida
- Research Site — Marietta, Georgia
- Research Site — Hines, Illinois
- Research Site — Fort Wayne, Indiana
- Research Site — Muncie, Indiana
- Research Site — Lexington, Kentucky
- Research Site — Annapolis, Maryland
- Research Site — Baltimore, Maryland
- Research Site — Towson, Maryland
- Research Site — Boston, Massachusetts
- Research Site — Detroit, Michigan
- Research Site — Grand Rapids, Michigan
- Research Site — Minneapolis, Minnesota
- Research Site — Summit, New Jersey
- Research Site — New Hyde Park, New York
- Research Site — Chapel Hill, North Carolina
- Research Site — Portland, Oregon
- Research Site — Philadelphia, Pennsylvania
- Research Site — Pittsburgh, Pennsylvania
- Research Site — Sioux Falls, South Dakota
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Small Cell Lung Cancer
- Ipilimumab and Nivolumab in Recurrent Extensive Stage Small Cell Lung Cancer After Receiving Platinum-based Chemotherapy — New Haven, Connecticut
- Placebo-controlled, Study of Concurrent Chemoradiation Therapy With Pembrolizumab Followed by Pembrolizumab and Olaparib in Newly Diagnosed Treatment-Naïve Limited-Stage Small Cell Lung Cancer (LS-SCLC) (MK 7339-013/KEYLYNK-013) — Chandler, Arizona
- Study of Tarlatamab in Combination With YL201 With or Without Anti-programmed Death Ligand 1 (PD-L1) in Participants With Extensive Stage (ES) Small Cell Lung Cancer (SCLC) — Irvine, California
- Pharmacogenomics ANDA SNP Clinical Study - Etoposide and Single Nucleotide Polymorphisms — Rockville, Maryland
- PF-07104091 as a Single Agent and in Combination Therapy — Clive, Iowa
Explore by condition: All Small Cell Lung Cancer clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.